New Clinical Trials Use Genetic Testing to Personalize Lung Cancer Treatment

Kaiser Permanente has begun enrolling lung cancer patients in two new clinical trials that profile tumors for genetic markers and then direct patients to the experimental medications that are most likely to be effective. The LUNG-MAP and ALCHEMIST clinical trials are available to all members who qualify at every medical center in Kaiser Permanente’s Northern California region.